News
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
Eastlake Behavioral Health Hospital Approved by Chula Vista Planning Commission
The Chula Vista Planning Commission today approved a new inpatient behavioral health hospital in the Eastlake community of Chula Vista. The Eastlake behavioral health hospital will be operated by a
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Premier, Inc. to Host Virtual Investor Day on November 17, 2021
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that the company will host its 2021 Virtual Investor Day on Wednesday, November 17, 2021
Premier, Inc. Reports Fiscal-Year 2022 First-Quarter Results
Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year 2022 first quarter ended September 30, 2021.
"We entered fiscal 2022 with strong momentum and are pleased with
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
Pipeline Health System, LLC Partners with Premier Inc.
Pipeline Health System, LLC (“Pipeline Health”), an independent network of hospitals across California, Texas and Illinois, has selected Premier Inc. (NASDAQ: PINC), a leading technology-enabled
Acadia Healthcare Reports Third Quarter 2021 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2021.
Third Quarter 2021 Results
The Company reported revenue of
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with
Premier, Inc. and Resilinc Expand Partnership to Enhance Supply Chain Visibility and Sustainability
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, and Resilinc, the leading supply chain monitoring, mapping and resiliency solution, today announced a new
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.20 per share of Class A common
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting from Oct. 24
Premier Inc. Releases Inaugural Sustainability Report
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today released its inaugural sustainability report detailing companywide initiatives focused on
Acadia Healthcare Names Osei Mevs as Vice President of Government Relations
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that J.L. Osei Mevs has been named Vice President of Government Relations. In this role, Mevs will oversee the Company’s government
Acadia Healthcare Names David Keys as Chief Development Officer
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that David M. Keys, CFA, has been named Chief Development Officer. Keys will focus on mergers & acquisitions, de novo development and
Acadia Healthcare Announces Date for Third Quarter 2021 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2021 results on Thursday, October 28, 2021, after the close of the market. Acadia will conduct
Acadia Healthcare Announces Retirement of Chief Executive Officer
The Board of Directors of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Debbie Osteen will retire as CEO. Ms. Osteen will continue to serve on Acadia’s Board of Directors and
Premier, Inc. to Report Fiscal 2022 First-Quarter Results and Host Conference Call on November 2, 2021
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 first quarter on Tuesday, November 2, 2021, at approximately 6:30 a.m. EDT. The company will
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Novocure to Report Third Quarter 2021 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Novocure’s management